Nomoto K, Eto M, Yanaga K, Nishimura Y, Maeda T, Nomoto K
Department of Immunology, Kyushu University, Fukuoka, Japan.
J Immunol. 1992 Oct 15;149(8):2668-74.
In a murine strain combination identical in H-2 Ag but disparate in minor histocompatibility (H) Ag consisting of C3H/He (C3H; H-2k, Mls-1b) mice as recipients and AKR/J (AKR; H-2k, Mls-1a) mice as donors, a permanent skin allograft tolerance can be achieved by the cyclophosphamide (CP)-induced tolerance system that consists of i.v. injection of donor spleen cells (day -2) and i.p. injection of CP 2 days later (day 0). Such permanent take of allografts in CP-induced tolerant mice was interfered with by intramuscular injection of cyclosporin A (CsA) from day -5 to day -1 and their grafts were rejected by 21 days after grafting. Mls-1a-reactive CD4+V beta 6+ T cells in the periphery, as the indicator to follow the kinetics of donor-reactive T cells, increased on day 0 and day 3 in the C3H mice treated with AKR spleen cells alone, whereas they disappeared rapidly from day 0 to day 3 in CP-induced tolerant mice. When CsA capable of interfering with IL-2 production and T cell proliferation was administered before CP treatment in CP-induced tolerance system, the number of CD4+V beta 6+ T cells in periphery did not increase on day 0 and 3, but increased on day 7 in contrast to the decreased number of those in CP-induced tolerant mice. On day 7, MLR against donor cells was decreased in CP-induced tolerant mice, but maintained in CsA-interfered tolerant mice. These result may indicate that the destruction of donor-Ag-stimulated, proliferating T cells by CP is interfered with by CsA, probably because CsA inhibits the proliferation of donor-reactive T cells at the time of CP treatment. Furthermore, these results also implicate that the protocol for immunosuppression with CsA and antimetabolites has to be designed carefully in clinical transplantation.
在一种H-2抗原相同但次要组织相容性(H)抗原不同的小鼠品系组合中,以C3H/He(C3H;H-2k,Mls-1b)小鼠作为受体,AKR/J(AKR;H-2k,Mls-1a)小鼠作为供体,通过环磷酰胺(CP)诱导的耐受系统可实现永久性皮肤同种异体移植耐受,该系统包括静脉注射供体脾细胞(第-2天),并在2天后(第0天)腹腔注射CP。从第-5天到第-1天肌肉注射环孢素A(CsA)会干扰CP诱导的耐受小鼠中同种异体移植的这种永久性存活,并且它们的移植物在移植后21天被排斥。外周血中对Mls-1a有反应的CD4 + Vβ6 + T细胞,作为追踪供体反应性T细胞动力学的指标,在仅用AKR脾细胞处理的C3H小鼠中于第0天和第3天增加,而在CP诱导的耐受小鼠中从第0天到第3天迅速消失。当在CP诱导的耐受系统中在CP处理前给予能够干扰IL-2产生和T细胞增殖的CsA时,外周血中CD4 + Vβ6 + T细胞的数量在第0天和第3天没有增加,但在第7天增加,这与CP诱导的耐受小鼠中这些细胞数量减少形成对比。在第7天,CP诱导的耐受小鼠中对供体细胞的混合淋巴细胞反应降低,但在CsA干扰的耐受小鼠中得以维持。这些结果可能表明,CsA干扰了CP对供体抗原刺激的增殖性T细胞的破坏,这可能是因为CsA在CP处理时抑制了供体反应性T细胞的增殖。此外,这些结果还表明,在临床移植中,必须仔细设计CsA和抗代谢物的免疫抑制方案。